Suppr超能文献

混合谱系白血病的发病机制。

The pathogenesis of mixed-lineage leukemia.

机构信息

Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.

出版信息

Annu Rev Pathol. 2012;7:283-301. doi: 10.1146/annurev-pathol-011811-132434. Epub 2011 Oct 17.

Abstract

Aggressive leukemias arise in both children and adults as a result of rearrangements to the mixed-lineage leukemia gene (MLL) located on chromosome 11q23. MLL encodes a large histone methyltransferase that directly binds DNA and positively regulates gene transcription, including homeobox (HOX) genes. MLL is involved in chromosomal translocations, partial tandem duplications, and amplifications, all of which result in hematopoietic malignancies due to sustained HOX expression and stalled differentiation. MLL lesions are associated with both acute myeloid leukemia and acute lymphoid leukemia and are usually associated with a relatively poor prognosis despite improved treatment options such as allogeneic hematopoietic stem cell transplantation, which underscores the need for new treatment regimens. Recent advances have begun to reveal the molecular mechanisms that drive MLL-associated leukemias, which, in turn, have provided opportunities for therapeutic development. Here, we discuss the etiology of MLL leukemias and potential directions for future therapy.

摘要

侵袭性白血病可在儿童和成人中由于混合谱系白血病基因(MLL)位于 11q23 染色体上的重排而发生。MLL 编码一种大型组蛋白甲基转移酶,可直接结合 DNA 并正向调节基因转录,包括同源盒(HOX)基因。MLL 参与染色体易位、部分串联重复和扩增,所有这些都会由于持续的 HOX 表达和分化停滞导致造血恶性肿瘤。MLL 病变与急性髓系白血病和急性淋巴细胞白血病都有关,尽管有改善的治疗选择,如异体造血干细胞移植,但预后通常较差,这突显了需要新的治疗方案。最近的进展开始揭示驱动 MLL 相关白血病的分子机制,这反过来又为治疗开发提供了机会。在这里,我们讨论了 MLL 白血病的病因和未来治疗的潜在方向。

相似文献

1
The pathogenesis of mixed-lineage leukemia.
Annu Rev Pathol. 2012;7:283-301. doi: 10.1146/annurev-pathol-011811-132434. Epub 2011 Oct 17.
2
The molecular biology of mixed lineage leukemia.
Haematologica. 2009 Jul;94(7):984-93. doi: 10.3324/haematol.2008.002436. Epub 2009 Jun 16.
6
MLL: a histone methyltransferase disrupted in leukemia.
Trends Mol Med. 2004 Oct;10(10):500-7. doi: 10.1016/j.molmed.2004.08.005.
7
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.
Nat Genet. 2002 Jan;30(1):41-7. doi: 10.1038/ng765. Epub 2001 Dec 3.
8
11q23 rearrangements in acute leukemia.
Leukemia. 1996 Jan;10(1):74-82.
9
Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocation.
Exp Hematol. 2020 May;85:13-19. doi: 10.1016/j.exphem.2020.04.008. Epub 2020 May 11.
10
Mouse models of MLL leukemia: recapitulating the human disease.
Blood. 2017 Apr 20;129(16):2217-2223. doi: 10.1182/blood-2016-10-691428. Epub 2017 Feb 8.

引用本文的文献

2
C-terminal fusion partner activity contributes to the oncogenic functions of YAP1::TFE3.
Sci Rep. 2025 Aug 31;15(1):32013. doi: 10.1038/s41598-025-17409-z.
5
HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia.
Leukemia. 2025 Feb;39(2):371-380. doi: 10.1038/s41375-024-02485-3. Epub 2024 Dec 4.
6
Elucidating the role of MLL1 nsSNPs: Structural and functional alterations and their contribution to leukemia development.
PLoS One. 2024 Oct 15;19(10):e0304986. doi: 10.1371/journal.pone.0304986. eCollection 2024.
7
Unraveling MLL1-fusion leukemia: Epigenetic revelations from an iPS cell point mutation.
J Biol Chem. 2024 Nov;300(11):107825. doi: 10.1016/j.jbc.2024.107825. Epub 2024 Sep 27.
8
Histone methyltransferase KMT2A: Developmental regulation to oncogenic transformation.
J Biol Chem. 2024 Oct;300(10):107791. doi: 10.1016/j.jbc.2024.107791. Epub 2024 Sep 18.
9
Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia.
Biomedicines. 2024 Aug 6;12(8):1768. doi: 10.3390/biomedicines12081768.
10
A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression.
Sci Adv. 2024 Aug 30;10(35):eado1432. doi: 10.1126/sciadv.ado1432. Epub 2024 Aug 28.

本文引用的文献

1
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Blood. 2011 May 5;117(18):4759-68. doi: 10.1182/blood-2010-12-327668. Epub 2011 Feb 25.
2
Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
Blood. 2011 Jun 9;117(23):6304-14. doi: 10.1182/blood-2009-07-234310. Epub 2010 Dec 29.
3
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Cancer Res. 2010 Dec 15;70(24):10234-42. doi: 10.1158/0008-5472.CAN-10-3294.
4
Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.
Mini Rev Med Chem. 2010 Oct;10(11):1058-70. doi: 10.2174/1389557511009011058.
5
The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures.
Leukemia. 2011 Jan;25(1):135-44. doi: 10.1038/leu.2010.249. Epub 2010 Oct 29.
6
Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
J Biol Chem. 2010 Dec 24;285(52):40690-8. doi: 10.1074/jbc.M110.172783. Epub 2010 Oct 20.
7
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Exp Hematol. 2011 Jan;39(1):77-86.e1-5. doi: 10.1016/j.exphem.2010.09.003. Epub 2010 Sep 18.
8
Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.
Nat Rev Cancer. 2010 Oct;10(10):721-8. doi: 10.1038/nrc2915. Epub 2010 Sep 16.
9
Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint.
Nature. 2010 Sep 16;467(7313):343-6. doi: 10.1038/nature09350. Epub 2010 Sep 5.
10
FLT3 inhibitors for the treatment of acute myeloid leukemia.
Clin Adv Hematol Oncol. 2010 Jun;8(6):429-36, 444.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验